Mymd Pharmaceuticals (NASDAQ:QCLS) Stock Falls 8% – Here’s Why

Mymd Pharmaceuticals, Inc. (NASDAQ:QCLS)’s share price traded down 8% during mid-day trading on Wednesday. The stock traded as low as $0.3910 and last traded at $0.3910. Approximately 165,870 shares traded hands during mid-day trading, a decline of 4% from the average daily volume of 173,338 shares. The stock had previously closed at $0.4250.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on QCLS shares. Weiss Ratings lowered shares of Mymd Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a research note on Thursday, October 29th. Wall Street Zen raised shares of Mymd Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 19th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Mymd Pharmaceuticals Stock Performance

The stock’s 50 day moving average price is $0.88.

Mymd Pharmaceuticals (NASDAQ:QCLS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.79) EPS for the quarter.

About Mymd Pharmaceuticals

TNF Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation.